Italia markets closed

Medigene AG (0QGJ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,2150+0,0100 (+0,83%)
Alla chiusura: 08:19AM BST
Schermo intero
Chiusura precedente1,2050
Aperto1,1950
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno1,1950 - 1,2150
Intervallo di 52 settimane1,1950 - 2,2500
Volume1.496
Media Volume128
Capitalizzazione29,837M
Beta (mensile su 5 anni)0,86
Rapporto PE (ttm)N/D
EPS (ttm)-0,4060
Prossima data utili15 ago 2024 - 19 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023

    Planegg/Martinsried, October 16, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the ESMO Congress 2023 being held on October 20-24, 2023, in Madrid, Spain. The data to be presented shows that optimal affinity T cell receptors (TCRs) when combined with Medigene’s PD1-41BB costimulatory switch protein (CSP), provides strong protect

  • GlobeNewswire

    Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

    Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed

  • GlobeNewswire

    Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

    Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costim